4-Aminopyridine

Applications

In the laboratory, 4-AP is a useful pharmacological tool in studying various potassium conductances in physiology and biophysics. It is a relatively selective blocker of members of Kv1 (Shaker, KCNA) family of voltage-activated K+ channels. However, 4-AP has been shown to potentiate voltage-gated Ca2+ channel currents independent of effects on voltage-activated K+ channels.

Convulsant activity

4-Aminopyridine is a potent convulsant and is used to generate seizures in animal models for the evaluation of antiseizure agents.

Vertebrate pesticide

4-Aminopyridine is also used under the trade name Avitrol as 0.5% or 1% in bird control bait. It causes convulsions and, infrequently, death, depending on dosage. The manufacturer says the proper dose should cause epileptic-like convulsions which cause the poisoned birds to emit distress calls resulting in the flock leaving the site; if the dose was sub-lethal, the birds will recover after 4 or more hours without long-term ill effect. The amount of bait should be limited so that relatively few birds are poisoned, causing the remainder of the flock to be frightened away with a minimum of mortality. A lethal dose will usually cause death within an hour. The use of 4-aminopyridine in bird control has been criticized by the Humane Society of the United States.

Medical use

| Drugs.com =

Fampridine has been used clinically in Lambert–Eaton myasthenic syndrome and multiple sclerosis. It acts by blocking voltage-gated potassium channels, prolonging action potentials and thereby increasing neurotransmitter release at the neuromuscular junction. The drug has been shown to reverse saxitoxin and tetrodotoxin toxicity in tissue and animal experiments. In calcium entry blocker overdose in humans, 4-aminopyridine can increase the cytosolic Ca2+ concentration very efficiently independent of the calcium channels.

Multiple sclerosis

Fampridine has been shown to improve visual function and motor skills and relieve fatigue in patients with multiple sclerosis (MS). However, the effect of the drug is strongly established for walking capacity only. Common side effects include dizziness, nervousness and nausea, and the incidence of adverse effects was shown to be less than 5% in all studies.

4-AP works as a potassium channel blocker. Strong potassium currents decrease action potential duration and amplitude, which increases the probability of conduction failure − a well documented characteristic of demyelinated axons. Potassium channel blockade has the effect of increasing axonal action potential propagation and improving the probability of synaptic vesicle release. A study has shown that 4-AP is a potent calcium channel activator and can improve synaptic and neuromuscular function by directly acting on the calcium channel beta subunit.

MS patients treated with 4-AP exhibited a response rate of 29.5% to 80%. A long-term study (32 months) indicated that 80-90% of patients who initially responded to 4-AP exhibited long-term benefits. Although improving symptoms, 4-AP does not inhibit progression of MS. Another study, conducted in Brazil, showed that treatment based on fampridine was considered efficient in 70% of the patients.

Spinal cord injury

Spinal cord injury patients have also seen improvement with 4-AP therapy. These improvements include sensory, motor and pulmonary function, with a decrease in spasticity and pain.

KCNA2-related disorders

4-Aminopyridine is a gene-targeted therapy option for KCNA2-related disorders with a gain-of-function (GOF) or some mix-of-function (MOF) gene mutations. It has shown to improve seizure control, gait, ataxia, alertness, and cognition. GOF KCNA2 disorders are caused by voltage-gated potassium channels in the central nervous system that stay open and allow too much flow of potassium currents. Some MOF KCNA2 disorders also act like GOF in regards to their flow of potassium through the channel which is why they may also benefit from 4-AP therapy. 4-AP acts by closing these channels and improves the natural flow of potassium through the neuron.

As of 2025 the use of 4-AP for KCNA2 is in an experimental stage, but it has shown significant improvement for most patients that have used it. Out of 13 documented patients, eight became seizure free, two others experienced a reduction in seizures, and 11 had improved gait, ataxia, alertness, cognition, or speech. Only one patient experienced side effects of increased seizures and no other symptoms were reported.

Authors of the first 4-AP KCNA2 study created an online tool to guide physicians in identifying which KCNA2 patients would benefit from this therapy. It is publicly accessible due to the importance for treating this disease from young age. See the article for details on accessing this information.

Tetrodotoxin poisoning

Clinical studies have shown that 4-AP is capable of reversing the effects of tetrodotoxin poisoning in animals, however, its effectiveness as an antidote in humans has not yet been determined.

Overdose

Case reports have shown that overdoses with 4-AP can lead to paresthesias, seizures, and atrial fibrillation.

Contraindications

4-aminopyridine is excreted by the kidneys. 4-AP should not be given to people with significant kidney disease (e.g., acute kidney injury or advanced chronic kidney disease) due to the higher risk of seizures with increased circulating levels of 4-AP.

Branding

The drug was originally intended, by Acorda Therapeutics, to have the brand name Amaya, however the name was changed to Ampyra to avoid potential confusion with other marketed pharmaceuticals.

Four of Acorda's patents pertaining to Ampyra were invalidated in 2017 by the United States District Court for the District of Delaware and a fifth patent expired in 2018. Since then, generic alternatives have been developed for the U.S. market.

The drug is marketed by Biogen Idec in Canada as Fampyra and as Dalstep in India by Sun Pharma.

Research

Parkinson's disease

Dalfampridine completed Phase II clinical trials for Parkinson's disease in July 2014.

References

References

1. (1948). "455. The strength of heterocyclic bases". Journal of the Chemical Society (Resumed).
2. (20 December 2019). "Ampyra- dalfampridine tablet, film coated, extended release".
3. (15 August 2018). "Fampyra 10 mg prolonged-release tablets - Summary of Product Characteristics (SmPC)".
4. (21 June 2022). "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017".
5. (22 June 2020). "Dalfampridine (Ampyra) Use During Pregnancy".
6. "4-AP".
7. (2002). "Aminopyridines for symptomatic treatment in multiple sclerosis". The Cochrane Database of Systematic Reviews.
8. (October 2008). "Sustained-release fampridine for symptomatic treatment of multiple sclerosis". The Annals of Pharmacotherapy.
9. (August 2011). "New Drugs: Fampridine". Australian Prescriber.
10. "Acorda Clinical Development and Product Pipeline".
11. "FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis".
12. "Ampyra".
13. "Notice of Decision for FAMPYRA".
14. (2007). "Ullmann's Encyclopedia of Industrial Chemistry". John Wiley & Sons.
15. (November 1989). "Molecular basis of functional diversity of voltage-gated potassium channels in mammalian brain". The EMBO Journal.
16. (January 1998). "Voltage-activated potassium channels in mammalian neurons and their block by novel pharmacological agents". General Pharmacology.
17. (December 2009). "Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit". The Journal of Biological Chemistry.
18. (March 1992). "Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice". Epilepsy Research.
19. (27 September 2007). "EPA Reregistration Eligibility Decision for 4-aminopyridine". U.S. Environmental Protection Agency.
20. "What is Avitrol?". Avitrol Corporation, Tulsa, Oklahoma, US.
21. (May 13, 2008). "Poisonous Solution: The Avitrol Problem". [[Humane Society of the United States]].
22. (July 2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacology & Therapeutics.
23. (July 2016). "4-Aminopyridine as a life-saving treatment in calcium channel antagonist intoxication". The Netherlands Journal of Medicine.
24. (July 1997). "4-Aminopyridine reverses saxitoxin (STX)- and tetrodotoxin (TTX)-induced cardiorespiratory depression in chronically instrumented guinea pigs". Fundamental and Applied Toxicology.
25. (November 1996). "Effects of 4-aminopyridine on saxitoxin intoxication". Toxicology and Applied Pharmacology.
26. [http://www.emedicine.com/emerg/topic342.htm Octopus Envenomations] at eMedicine.com
27. (November 2019). "Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis". CNS Drugs.
28. (1 Jun 2017). "Fampyra: EPAR - Product Information". European Medicines Agency.
29. (17 September 2018). "Fampyra EPAR".
30. (December 2009). "Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit". The Journal of Biological Chemistry.
31. (August 1, 2016). "Real-life experience with fampridine (Fampyra) for patients with multiple sclerosis and gait disorders". NeuroRehabilitation.
32. (June 1993). "4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety". Clinical Neuropharmacology.
33. (September 2021). "4-Aminopyridine is a promising treatment option for patients with gain-of-function KCNA2-encephalopathy". Science Translational Medicine.
34. (2025-08-07). "Aminopyridine treatment for an adult case of developmental and epileptic encephalopathy with a gain-of-function mutation in KCNA2". Genes & Diseases.
35. (April 2015). "De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy". Nature Genetics.
36. (September 2021). "A Novel KCNA2 Variant in a Patient with Non-Progressive Congenital Ataxia and Epilepsy: Functional Characterization and Sensitivity to 4-Aminopyridine". International Journal of Molecular Sciences.
37. (2021-09-02). "Potential Treatment for Rare Genetic Epilepsy Discovered".
38. "use of 4-aminopyridine in kcna2 epilepsy and neurodevelopmental disorder".
39. (March 1996). "Atypical presentation of 4-aminopyridine overdose". Annals of Emergency Medicine.
40. (February 2006). "An unusual case of 4-aminopyridine toxicity". The Journal of Emergency Medicine.
41. (January 22, 2010). "FDA Approves Dalfampridine to Improve Walking in Multiple Sclerosis". [[Medscape]].
42. "US courts invalidates Dalfampridine patents".
43. (7 October 2019). "Supreme Court declines to hear Acorda appeal of adverse Ampyra patent ruling".
44. (26 November 2014). "Fampyra Drug Monograph". Biogen Idec Canada Inc..
45. "Dalstep 10mg Registration Details".
46. {{ClinicalTrialsGov. NCT01491022. A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
47. Shinkichi Shimizu, Nanao Watanabe, Toshiaki Kataoka, Takayuki Shoji, Nobuyuki Abe, Sinji Morishita, Hisao Ichimura "Pyridine and Pyridine Derivatives" in "Ullmann's Encyclopedia of Industrial Chemistry" 2007; John Wiley & Sons: New York.
48. (1954). "The Synthesis of Compounds for the Chemotherapy of Tuberculosis. Iv. The Amide Function". The Journal of Organic Chemistry.